Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cell Therapeutics gets global rights to SBIO's Phase III-ready pacritinib

Executive Summary

Cell Therapeutics Inc. (CTI) has licensed exclusive worldwide rights to SBIO Pte. Ltd.’s (cancer drug developer) oral JAK2 inhibitor pacritinib, which is entering Phase III trials for primary myelofibrosis (MF) or MF secondary to other myeloproliferative neoplasms (polycythemia vera or essential thrombocythemia).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register